Who Should Be Monitored for PML While on Tysabri?

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

From General Health Education to Specialized Risk Awareness

If you or a loved one is taking Tysabri, understanding the risk of progressive multifocal leukoencephalopathy (PML) is crucial. This page reviews current research on who may need closer monitoring based on factors like JCV antibody status and prior immunosuppressant use, building on a tradition of patient education that helps individuals navigate complex treatment decisions.

Understanding Tysabri and Its Link to PML

Tysabri (natalizumab) is a monoclonal antibody used to treat multiple sclerosis and Crohn's disease. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), a severe opportunistic viral infection of the brain caused by the JC virus (JCV). PML typically occurs in immunocompromised individuals and usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The U.S. Food and Drug Administration (FDA) has issued a boxed warning for Tysabri, highlighting this risk and mandating that healthcare professionals monitor patients for any new signs or symptoms suggestive of PML, with immediate withholding of dosing at the first indication (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Clinical presentation of PML can include progressive neurological deficits such as weakness, cognitive decline, visual disturbances, and coordination problems. Diagnosis is confirmed through brain imaging, typically MRI, and detection of JCV DNA in cerebrospinal fluid or brain biopsy (https://pubmed.ncbi.nlm.nih.gov/40922664/). A retrospective national cohort study of 456 PML cases observed between 1987 and 2024 described demographic, clinical, radiological, and laboratory characteristics, noting that PML is a severe demyelinating disease affecting immunocompromised individuals (https://pubmed.ncbi.nlm.nih.gov/40922664/). The study included patients with definite or clinico-radiological diagnoses, underscoring the importance of early recognition.

Pharmacological Mechanism and Risk Factors

The pharmacological mechanism linking Tysabri to PML involves its action as an alpha-4 integrin antagonist. Tysabri binds to alpha-4 integrin on the surface of immune cells, preventing their migration across the blood-brain barrier into the central nervous system. This reduces inflammation in multiple sclerosis but also impairs immune surveillance against JCV, allowing the virus to reactivate and cause PML in the brain. The FDA label identifies three key risk factors for PML in Tysabri-treated patients: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Patients who are anti-JCV antibody positive have a higher risk for developing PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). In clinical trials, PML occurred in three patients: two among 1869 multiple sclerosis patients treated for a median of 120 weeks (who also received interferon beta-1a), and one after eight doses in a Crohn's disease patient (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Adequacy of Warnings and Legal Considerations

The adequacy of warnings regarding Tysabri and PML is a critical risk consideration. The FDA boxed warning explicitly states that Tysabri increases the risk of PML and that risk factors should be considered when initiating and continuing treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The label also mandates that Tysabri is available only through a restricted distribution program called the TOUCH Prescribing Program, which aims to ensure that patients are informed of the risks and that monitoring occurs (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Despite these measures, questions may arise about whether patients and healthcare providers fully understand the magnitude of risk, especially given the potential for severe outcomes. The timeline between exposure and documented harm is variable; PML can occur after months to years of treatment, with longer duration increasing risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). In clinical trials, cases were observed after 8 doses (approximately 8 weeks) and after a median of 120 weeks (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). For patients who develop PML after Tysabri treatment, attorney-related considerations may include evaluating whether the risks were adequately communicated and whether monitoring protocols were followed. The FDA label emphasizes that healthcare professionals should monitor patients for any new sign or symptom suggestive of PML and withhold Tysabri immediately (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Failure to do so could be a factor in legal claims. Additionally, the restricted distribution program is designed to mitigate risk, but its implementation may vary. Patients affected by PML may seek legal counsel to explore options regarding compensation for medical costs, disability, and other damages. The severe nature of PML, which usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962), underscores the importance of timely and accurate risk communication.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is Tysabri and how is it linked to PML?

Tysabri (natalizumab) is a monoclonal antibody used to treat multiple sclerosis and Crohn's disease. It increases the risk of progressive multifocal leukoencephalopathy (PML), a severe brain infection caused by the JC virus. The FDA has issued a boxed warning for this risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

What are the risk factors for developing PML while on Tysabri?

Key risk factors include the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

How is PML diagnosed?

Diagnosis is confirmed through brain imaging (typically MRI) and detection of JCV DNA in cerebrospinal fluid or brain biopsy (https://pubmed.ncbi.nlm.nih.gov/40922664/).

What legal options are available for individuals who developed PML after Tysabri treatment?

Affected individuals may seek legal counsel to evaluate whether risks were adequately communicated and monitoring protocols followed. Potential claims could involve failure to warn or negligence, leading to compensation for medical costs, disability, and other damages.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.